CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题：Selinexor-based regimens in patients with multiple myeloma after prior anti-B-cell maturation antigen treatment.
Selinexor-based regimens in patients with multiple myeloma after prior anti-B-cell maturation antigen treatment.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
在既往接受过治疗的多发性骨髓瘤中，尤其是抗B细胞成熟抗原（BCMA）治疗后的治疗序贯缺乏共识。早期关于selinexor（X）方案的报道显示，在早期治疗中以及抗BCMA靶向CAR-T 细胞治疗后具有显著疗效。在此，我们呈现了11例重度经治患者的数据，这些患者主要接受了BCMA-抗体药物偶联物治疗。我们观察到，含X方案效力强，可实现持久缓解，与患者既往抗BCMA治疗相比，总体缓解率和临床获益率以及中位无进展生存期在数值上更高，尽管其在治疗过程中使用得更晚。在一个未满足需求不断演变的领域，这些数据再次证实了在更广泛的抗BCMA治疗后基于X方案的疗效。
There is a lack of consensus on therapy sequencing in previously treated multiple myeloma, particularly after anti-B-cell maturation antigen (BCMA) therapy. Earlier reports on selinexor (X) regimens demonstrated considerable efficacy in early treatment, and after anti-BCMA-targeted chimeric antigen receptor-T cell therapy.
Here, we present data from 11 heavily pretreated patients who predominantly received BCMA-antibody-drug conjugate therapy.
We observe that X-containing regimens are potent and achieve durable responses with numerically higher overall response and clinical benefit rates, as well as median progression free survival compared to patients' prior anti-BCMA therapies, despite being used later in the treatment course. In an area of evolving unmet need, these data reaffirm the efficacy of X-based regimens following broader anti-BCMA therapy.
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。
